Home » Stocks » Rapt Therapeutics

Rapt Therapeutics, Inc. (RAPT)

Stock Price: $28.05 USD 0.31 (1.12%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 683.68M
Revenue (ttm) 935,000
Net Income (ttm) n/a
Shares Out 24.37M
EPS (ttm) -4.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $28.05
Previous Close $27.74
Change ($) 0.31
Change (%) 1.12%
Day's Open 28.61
Day's Range 27.02 - 29.83
Day's Volume 104,418
52-Week Range 10.52 - 51.21

More Stats

Market Cap 683.68M
Enterprise Value 545.48M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 24.37M
Float 13.32M
EPS (basic) n/a
EPS (diluted) -4.70
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 208,605
Short Ratio 1.35
Short % of Float 1.91%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 731.21
PB Ratio 6.07
Revenue 935,000
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 138.20M
Net Cash / Share 5.67
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -26.93%
ROE -48.34%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$37.40*
(33.33% upside)
Low
33.0
Current: 28.05
High
44.0
Target: 37.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-43.63-36.95-29.33
Net Income-43.00-36.15-29.12
Shares Outstanding4.350.620.43
Earnings Per Share-9.89-58.09-67.45
Operating Cash Flow-35.47-32.95-27.12
Capital Expenditures-0.84-3.50-1.12
Free Cash Flow-36.32-36.45-28.25
Cash & Equivalents77.3863.8047.52
Net Cash / Debt77.3863.8047.52
Assets84.6069.6150.39
Liabilities11.48167113
Book Value73.12-97.11-62.41
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Rapt Therapeutics, Inc.
Country United States
Employees 68
CEO Brian Russell Wong

Stock Information

Ticker Symbol RAPT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RAPT

Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.